143 related articles for article (PubMed ID: 21122099)
1. Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.
Sieuwerts AM; Ansems M; Look MP; Span PN; de Weerd V; van Galen A; Foekens JA; Adema GJ; Martens JW
Breast Cancer Res; 2010; 12(6):R103. PubMed ID: 21122099
[TBL] [Abstract][Full Text] [Related]
2. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
[TBL] [Abstract][Full Text] [Related]
3. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
4. DC-SCRIPT is a novel regulator of the tumor suppressor gene CDKN2B and induces cell cycle arrest in ERα-positive breast cancer cells.
Ansems M; Søndergaard JN; Sieuwerts AM; Looman MW; Smid M; de Graaf AM; de Weerd V; Zuidscherwoude M; Foekens JA; Martens JW; Adema GJ
Breast Cancer Res Treat; 2015 Feb; 149(3):693-703. PubMed ID: 25663546
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
6. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
[TBL] [Abstract][Full Text] [Related]
7. CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T; Sieuwerts AM; Veldscholte J; Meijer-van Gelder ME; Smid M; Brinkman A; den Dekker AT; Leroy IM; van Ijcken WF; Sleijfer S; Foekens JA; Dorssers LC
Br J Cancer; 2009 Dec; 101(11):1824-32. PubMed ID: 19904269
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer.
Meijer D; Sieuwerts AM; Look MP; van Agthoven T; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2008 Mar; 15(1):101-11. PubMed ID: 18310279
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
10. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
11. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
[TBL] [Abstract][Full Text] [Related]
12. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
Girault I; Lerebours F; Amarir S; Tozlu S; Tubiana-Hulin M; Lidereau R; Bièche I
Clin Cancer Res; 2003 Apr; 9(4):1259-66. PubMed ID: 12684393
[TBL] [Abstract][Full Text] [Related]
14. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
[TBL] [Abstract][Full Text] [Related]
16. Using second harmonic generation to predict patient outcome in solid tumors.
Burke K; Smid M; Dawes RP; Timmermans MA; Salzman P; van Deurzen CH; Beer DG; Foekens JA; Brown E
BMC Cancer; 2015 Nov; 15():929. PubMed ID: 26603532
[TBL] [Abstract][Full Text] [Related]
17. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis.
Tong ZJ; Shi NY; Zhang ZJ; Yuan XD; Hong XM
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28667103
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.
Sieuwerts AM; Lyng MB; Meijer-van Gelder ME; de Weerd V; Sweep FC; Foekens JA; Span PN; Martens JW; Ditzel HJ
Mol Oncol; 2014 Dec; 8(8):1679-89. PubMed ID: 25081647
[TBL] [Abstract][Full Text] [Related]
20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
